Schrödinger, Inc. (SDGR)

NASDAQ: SDGR · Real-Time Price · USD
11.80
+0.50 (4.42%)
At close: Feb 25, 2026, 4:00 PM EST
11.78
-0.02 (-0.17%)
After-hours: Feb 25, 2026, 7:49 PM EST
Market Cap869.24M -52.6%
Revenue (ttm)255.87M +23.3%
Net Income-103.27M
EPS-1.41
Shares Out 73.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,492,120
Open11.61
Previous Close11.30
Day's Range11.46 - 12.00
52-Week Range11.11 - 27.63
Beta1.56
AnalystsBuy
Price Target24.33 (+106.19%)
Earnings DateFeb 25, 2026

About SDGR

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration an... [Read more]

Sector Healthcare
IPO Date Feb 6, 2020
Employees 891
Stock Exchange NASDAQ
Ticker Symbol SDGR
Full Company Profile

Financial Performance

In 2025, Schrödinger's revenue was $255.87 million, an increase of 23.29% compared to the previous year's $207.54 million. Losses were -$103.27 million, -44.81% less than in 2024.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for SDGR stock is "Buy." The 12-month stock price target is $24.33, which is an increase of 106.19% from the latest price.

Price Target
$24.33
(106.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Schrödinger, Inc. (SDGR) Q4 2025 Earnings Call Transcript

Schrödinger, Inc. (SDGR) Q4 2025 Earnings Call Transcript

3 hours ago - Seeking Alpha

Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 finan...

7 hours ago - Business Wire

Schrödinger to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 46th Annual Health Care Conference: Firesid...

1 day ago - Business Wire

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: GMABHSTM
6 days ago - Benzinga

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 13, 2026, the company granted (i) non-statutory stock options to purchase 9,600 shares of the company's comm...

7 days ago - Business Wire

Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The ...

14 days ago - Business Wire

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to...

6 weeks ago - Business Wire

Schrodinger to offer Eli Lilly's AI drug discovery platform on its software

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.

Other symbols: LLY
6 weeks ago - Reuters

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discov...

6 weeks ago - Business Wire

Unlocking Hidden Value In Schrodinger's Box

Schrodinger's shares have declined sharply in recent weeks, due largely to soft guidance for the fourth quarter. There is little reason to believe that this is anything more than a temporary headwind ...

3 months ago - Seeking Alpha

Schrödinger to Present at Jefferies London Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The live presentation wil...

3 months ago - Business Wire

Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript

Schrödinger, Inc. ( SDGR) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jaren Madden - Chief Corporate Affairs Officer & Head of Investor Relations Ramy Farid - CEO, Preside...

4 months ago - Seeking Alpha

Schrödinger Reports Third Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third quarter with software reven...

4 months ago - Business Wire

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Copernic Catalysts, Inc. (Copernic) today announced that, in collaboration with Schrödinger, Inc. (Nasdaq: SDGR), the companies have surpassed the final technical mi...

4 months ago - Business Wire

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a co...

4 months ago - Business Wire

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Ramy Farid - CEO, President & Director Karen Akinsanya - Pr...

6 months ago - Seeking Alpha

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live...

6 months ago - Business Wire

Schrödinger Announces Discontinuation of SGR-2921 Program

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Pha...

6 months ago - Business Wire

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jaren Irene Madden - Chief Corporate Affairs Officer & Head of Investor Relations Karen...

7 months ago - Seeking Alpha

Schrödinger Reports Second Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the quarter ended June 30, 2025.

7 months ago - Business Wire

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a con...

7 months ago - Business Wire

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

The Material Informatics Companies Quadrant presents an in-depth analysis of the global material informatics market. This industry review highlights leading companies, technological advancements, and ...

7 months ago - GlobeNewsWire

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus...

7 months ago - Business Wire

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administ...

8 months ago - Business Wire

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Schrödinger's SGR-1505 Phase 1 data shows encouraging safety and niche efficacy, especially in BTKi-resistant Waldenström macroglobulinemia patients. Despite a headline 22% ORR, the nuanced data suppo...

9 months ago - Seeking Alpha